46 completed. 46 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Completed 46 |
Follow Chickenpox: new trials by email Literature Review of Chickenpox trials Research Report on Chickenpox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines Varicella Vaccine, Varivax - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 642 | 2024-02-29 | 2025-01-27 |
| Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd., Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd - Varicella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 2480 | 2022-02-13 | 2023-12-29 |
| Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) VARIVAX™ - Varicella | Phase 3 | Completed | Merck Sharp & Dohme LLC | 150 | 2019-03-01 | 2021-04-06 |
| An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization Investigational live attenuated varicella vaccine - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 1193 | 2018-07-11 | 2021-12-09 |
| Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II® - Varicella | Phase 3 | Completed | Merck Sharp & Dohme LLC | 600 | 2017-10-17 | 2021-01-27 |
| A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines Investigational live attenuated varicella vaccine, diluent of lyophilized vaccine - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 5997 | 2016-08-01 | 2017-10-26 |
| Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age NBP608, Varivax - Varicella | Phase 3 | Completed | SK Bioscience Co., Ltd. | 516 | 2016-07-14 | 2019-05-08 |
| A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age. Varilrix HSA-free, Varilrix™ - Chicken-pox Illness (Varicella Virus Disease), Chickenpox | Phase 3 | Completed | GlaxoSmithKline | 1236 | 2015-11-13 | 2019-11-25 |
| Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. MMR Bio-Manguinhos, MMR GlaxoSmithKline - Measles, Mumps | Phase 3 | Completed | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1560 | 2015-02-01 | 2016-07-11 |
| A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine Vaccine manufactured at commercialized scale, Vaccine manufactured at trial-scale - Varicella | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 1197 | 2014-04-07 | 2018-06-13 |
| Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) VARIVAX™ New Seed Process, VARIVAX™ 2007 process, M-M-R II™ - Varicella | Phase 3 | Completed | Merck Sharp & Dohme LLC | 611 | 2014-03-07 | 2018-10-30 |
| Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) MMRV (AMP), MMRV (2006 process) - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1412 | 2012-06-05 | 2018-10-31 |
| Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children PriorixTetra™, Meningitec - Rubella, Varicella | Phase 3 | Completed | GlaxoSmithKline | 716 | 2012-02-06 | 2018-08-17 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV JE-CV Vaccine, Varicella Vaccine - Japanese Encephalitis, Varicella | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 454 | 2010-08-25 | 2022-03-28 |
| Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™ - Varicella, Rubella | Phase 3 | Completed | GlaxoSmithKline | 450 | 2009-11-09 | 2018-06-08 |
| Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) Varicella Virus Vaccine Live (2007 Process) (Oka/Merck), Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck), Measles, Mumps, and Rubella Virus Vaccine Live (MMR) - Varicella | Phase 3 | Completed | Merck Sharp & Dohme LLC | 598 | 2009-01-01 | 2017-04-12 |
| Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 PriorixTM, VarilrixTM, Priorix-Tetra® - Measles, Varicella | Phase 3 | Completed | GlaxoSmithKline | 475 | 2008-10-01 | 2018-06-08 |
| Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers MenACWY-CRM + MMRV, MMRV, MenACWY-CRM - Meningococcal Infections | Phase 3 | Completed | Novartis Vaccines | 1630 | 2008-02-01 | 2013-04-19 |
| Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) ProQuad® manufactured with recombinant Human Albumin (rHA) - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1620 | 2007-11-29 | 2018-01-30 |
| Safety Study of ProQuad® rHA in Infants (V221-037) ProQuad® - Measles, Mumps | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3388 | 2007-10-24 | 2017-10-17 |
Showing 20 of 46. Sign in to see all of them.
Measles (25) · Mumps (25) · Rubella (25) · Haemophilus Infections (4) · Herpes Zoster (4) · Meningitis, Meningococcal (3) · AIDS-Related Complex (2) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Communicable Diseases (1) · Diphtheria (1) · Encephalitis, Japanese (1) · Hepatitis B (1) · Herpesviridae Infections (1)
DNA Virus Infections (46) · Infections (46) · Varicella Zoster Virus Infection (46) · Herpesviridae Infections (45) · Virus Diseases (45) · RNA Virus Infections (28) · Mononegavirales Infections (25) · Morbillivirus Infections (25) · Mouth Diseases (25) · Paramyxoviridae Infections (25) · Parotid Diseases (25) · Parotitis (25) · Rubivirus Infections (25) · Rubulavirus Infections (25) · Salivary Gland Diseases (25)
measles, mumps, rubella, varicella vaccine (14) · Chickenpox Vaccine (6) · Measles-Mumps-Rubella Vaccine (6) · Herpes Zoster Vaccine (3) · Meningococcal Vaccines (3) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Priorix-Tetra vaccine (2) · Vaccines, Attenuated (2) · 5-propynylarabinofuranosyluracil (1) · Acyclovir (1) · Adenosine Monophosphate (1) · Desipramine (1) · Duration of Therapy (1) · Famciclovir (1) · Hepatitis A Vaccines (1)
Merck Sharp & Dohme LLC (18) · GlaxoSmithKline (11) · Sanofi Pasteur, a Sanofi Company (4) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (4) · Bristol-Myers Squibb (1) · Glaxo Wellcome (1) · National Center for Research Resources (NCRR) (1) · Novartis (1) · Novartis Vaccines (1) · SK Bioscience Co., Ltd. (1) · Shanghai Institute Of Biological Products (1) · The Hospital for Sick Children (1) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (1)
United States (8) · Germany (7) · China (3) · Italy (3) · Philippines (3) · Czechia (2) · Russia (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Costa Rica (1) · Estonia (1) · France (1)
Shengli Xia (2) · Anne Fiquet, MD (1) · Eliane Matos Santos (1) · Nancy Nazaire Bermal, MD (1) · Rommel Crisenio M. Lobo, MD (1) · Shengli Xia, Master (1) · Srinivasa N. Raja (1) · Upton Allen (1)
PMID 16452343, PMID 16567978, PMID 16804432, PMID 17502347, PMID 19273678, PMID 19366435, PMID 22123890, PMID 22406278, PMID 22772170, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 29087781, PMID 29325161, PMID 30481110, PMID 30616012, PMID 30765242, PMID 32429738, PMID 33736915, PMID 34473594, PMID 34702124, PMID 35632416
2004 (1), 2017 (1), 2019 (1)